A controlled study of $9\alpha,11\beta$ -PGF₂ (a prostaglandin D₂ metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge

Grażyna Bochenek, MD, PhD, Krzysztof Nagraba, PhD, Ewa Niżankowska, MD, PhD, and Andrzej Szczeklik, MD, PhD Cracow, Poland

Asthma, rhinitis,
other respiratory
diseases

Background: Prostaglandin D₂ (PGD₂) is the predominant cyclooxygenase product of mast cells, the number of which is increased in bronchial asthma. Release of PGD₂ might reflect mast cell activation and disordered function of the asthmatic lung.

Objective: We sought to determine blood and urinary levels of $9\alpha,11\beta$ -PGF₂, a major stable PGD₂ metabolite in 2 well-defined phenotypes of asthma, aspirin-induced asthma (AIA) and aspirin-tolerant asthma (ATA), and in healthy control subjects and to study the effects of aspirin on PGD₂ release.

Methods: Using gas chromatography/mass spectrometry, we determined plasma and urinary concentrations of $9\alpha,11\beta$ -PGF₂ at baseline in 131 stable asthmatic patients, 65 of whom had AIA and 66 of whom had ATA. Fifty healthy nonatopic subjects served as the control group. The measurements were also performed after an aspirin challenge in 26 of 65 patients with AIA and in 24 of 50 control subjects.

Results: At baseline, patients with AIA had significantly higher plasma levels of $9\alpha,11\beta$ -PGF₂ than either patients with ATA or healthy subjects. A similar significant elevation of serum tryptase was observed in patients with AIA compared with patients with ATA and control subjects. Mean urinary $9\alpha,11\beta$ -PGF₂ values did not differ among the 3 groups. In patients with AIA, as opposed to healthy subjects, aspirin challenge invariably precipitated a clinical reaction, accompanied in most patients by a further rise in plasma levels of PGD₂ metabolite and tryptase.

Conclusions: In stable AIA, though not in ATA, there is a steady release of PGD₂ into the blood, accompanied by the release of tryptase. Aspirin enhances this reaction in most patients. Release of bronchoconstrictive PGD₂ might contribute to the severe clinical course of AIA. (J Allergy Clin Immunol 2003;111:743-9.)

Key words: Prostaglandin D₂, $9\alpha,11\beta$ -PGF₂, mast cells, aspirin-induced asthma, tryptase, leukotriene E₄

Abbreviations used

AIA:	Aspirin-induced asthma
ASA:	Aspirin
ATA:	Aspirin-tolerant asthma
COX:	Cyclooxygenase
DP:	Prostaglandin D receptor
GC-NICI-MS:	Gas chromatography–negative-ion chemical ionization–mass spectrometry
GTP:	Guanosine triphosphate
LTE ₄ :	Leukotriene E ₄
NSAID:	Nonsteroidal anti-inflammatory drug

Prostaglandin D₂ (PGD₂) is the predominant cyclooxygenase metabolite of arachidonic acid in mast cells. It is also synthesized by human alveolar macrophages but not by basophils. PGD₂ is released into human airways during acute allergen challenge¹ and causes bronchoconstriction. PGD₂ elicits its biologic effects through interaction with the specific PGD₂ (DP) receptor, a heterotrimeric guanosine triphosphate-binding, protein-coupled, rhodopsin-type receptor.² Expression of this receptor in bronchial and alveolar epithelial cells is increased in the asthmatic airway. Mice with a disrupted DP gene (DP^{−/−}) do not develop asthmatic attacks in an ovalbumin-induced asthma model.³ In addition to being produced in the lung, PGD₂ is synthesized in various other tissues in response to allergic stimuli.^{4,5} Naturally occurring derivatives of PGD₂ bind to the peroxisome proliferator-activated receptor-γ and stimulate transcription of target genes.⁶ Mast cells are often found in close proximity to blood vessels,⁷ and these cells accumulate in coronary plaques of infarct-related coronary arteries.⁸

Of the mediators synthesized in mast cells, histamine and tryptase measurements have been introduced into clinical studies. Elevation of their levels in body fluids is considered to reflect mast cell activation.^{9,10} As opposed to histamine and tryptase, clinical estimation of PGD₂ has been limited to sporadic measurements, obtained mostly from urine samples.¹¹⁻¹⁴ In the present study, we focus on blood and urinary levels of the PGD₂ stable metabolite in 2 distinct types of asthma: aspirin-induced asthma (AIA) and aspirin-tolerant asthma (ATA). The kinetics of PGD₂ release in response to aspirin (ASA) challenge in hypersensitive patients has been also addressed.

From the Department of Medicine, Jagiellonian University School of Medicine.

Supported by Polish State Research Council grant no. 6PO5B14021.

Received for publication September 3, 2002; revised November 29, 2002; accepted for publication January 14, 2003.

Reprint requests: Andrzej Szczeklik, MD, Department of Medicine, Jagiellonian University School of Medicine, 31-066 Cracow, Skawińska 8, Poland.

© 2003 Mosby, Inc. All rights reserved.

0091-6749/2003 \$30.00 + 0

doi:10.1067/mai.2003.1387

TABLE I. Clinical characteristics of the patients

	ATA (n = 66): mean $\pm$ SD (range)	AIA (n = 65): mean $\pm$ SD (range)	HC (n = 50): mean $\pm$ SD (range)
Age (y)	34.6 $\pm$ 12.9 (19-70)	41.6 $\pm$ 12.4 (17-63)	35.6 $\pm$ 9.3 (25-61)
Male/female	27/39	24/41	17/33
Duration of asthma (y)	10.6 $\pm$ 9.6 (0.5-47)	9.9 $\pm$ 7.1 (1-33)	
FEV ₁			
Baseline (mL)	3138 $\pm$ 867	2725 $\pm$ 783	
Percent predicted	92.5 $\pm$ 14.5	84.9 $\pm$ 14.3	
Positive skin prick test results (n)	55	29	0
Total IgE, geometric mean $\pm$ SD (IU/mL)	129.3 $\pm$ 296.8	85.8 $\pm$ 297.5	38.8 $\pm$ 65.2
Inhaled steroids			
No. of users	45	58	
Dose (μ g/d)	1000 (250-2000)	1090 (320-2000)	
Oral steroids			
No. of users	20	25	
Dose (mg/d)	10.6 (2-16)	8.4 (2-20)	

ATA, Aspirin-tolerant asthma; AIA, aspirin-induced asthma; HC, healthy control subjects.

METHODS

Subjects

Three groups of subjects were studied. The first group consisted of 66 asthmatics who tolerated ASA (ATA). Within the previous 2 years each of them had occasionally used ASA and denied any adverse effects when specifically queried. In 35 of them selected at random, an ASA challenge test was performed; results were negative in all cases. The second group comprised 65 patients with AIA. Their disease developed according to a pattern characterized by a sequence of symptoms.¹⁵ All had had at least 1 episode of asthma attack after ingestion of ASA or other nonsteroidal anti-inflammatory drugs (NSAIDs), and the diagnosis was confirmed by oral ASA provocation tests, performed within 1 year before the study. All patients had stable asthma, and none had experienced an exacerbation thereof or a respiratory tract infection in the 6 weeks preceding the study.

The control group consisted of 50 healthy nonatopic subjects with no history of asthma or allergy. Both skin prick tests to common aeroallergens and a qualitative in vitro assay for determination of specific IgE antibodies were negative in all subjects. They were found to tolerate NSAIDs and had no history of adverse reactions to ASA and other ASA-like drugs. The patients' clinical characteristics are given in Table I.

Oral challenge test with ASA

During the study, an oral challenge test with ASA was performed in 26 of 65 patients with AIA and in 35 of 66 patients with ATA. It was pursued for 2 consecutive days, as previously described,¹⁶ subject to minor modifications. On the first day, placebo was administered, the dose consisting of 2 capsules spaced 2.5 hours apart. FEV₁ was measured every 30 minutes. If variations in FEV₁ of >15% occurred, the patient was excluded from further study because of bronchial instability. On the second day, each patient received increasing doses of ASA (27, 44, 117, and 312 mg) every 2.5 hours until a cumulative dose of 500 mg had been reached. FEV₁ was measured before the first dose and subsequently every 30 minutes. Patients were observed for the following clinical symptoms: bronchospasm, tightness of chest, wheezing, rhinorrhea, nasal congestion, ocular injection, periorbital swelling, and erythema of the skin. The challenge was interrupted if a decrease of $\geq 20\%$ in FEV₁ occurred, with or without extrabronchial symptoms, or when the maximum cumulative dose of ASA had been reached. The test

result was considered positive in the former case and negative in the latter. The cumulative dose causing a 20% fall in FEV₁ was calculated and recorded as PD₂₀. Provocations always started between 8:00 AM and 8:30 AM. Short-acting β_2 -agonists were not used 8 hours before the challenge. Long-acting β_2 -agonists and theophylline were withdrawn for 24 hours. It was recommended that short-acting antihistamines and cromones not be taken 5 days before the challenge.

In the control group a single dose of 100 mg of ASA, corresponding to the mean PD₂₀ for the AIA group, was administered to 10 subjects. Several weeks later the same 10 subjects received a single dose of 600 mg of ASA. The administration of each ASA dose was preceded a day earlier by a single dose of placebo. In another instance, 14 of 50 healthy subjects received 3 doses of ASA within a single day—ie, 100 mg in the morning, 600 mg 5 hours later, and 600 mg after the next 5 hours (total dose of ASA, 1300 mg).

Blood collection

Blood samples were taken at baseline from all subjects. Only from 26 patients with AIA who had undergone the ASA challenge were blood samples obtained before the provocation and at 5, 30, 60, and 120 minutes thereafter, after a fall in FEV₁ of $\geq 20\%$ was reported. On a placebo day, blood was sampled after administration of the second placebo capsule within the same time intervals as after ASA administration.

From the control subjects, blood samples were taken before and at 15, 30, 60, and 120 minutes after administration of a single dose of ASA or placebo. When 3 doses of ASA or placebo were administered within a single day, the samples were collected before the first dose, 5 hours later (ie, before the second dose of ASA), and subsequently 24 hours after the administration of the first dose.

For 9 α ,11 β -PGF₂ measurement, blood samples were immediately centrifuged at 3500 rpm for 10 minutes. To 1 mL of plasma, 500 pg of deuterium-labeled PGF_{2 α} ([²H₄]PGF_{2 α}) as an internal standard was added. Samples were immediately processed or stored at -80°C until assayed (not in excess of 2 months).

Urine collection

From all subjects urine samples were collected at baseline after a 2-hour accumulation of urine in the bladder. Only from 26 patients with AIA who were undergoing ASA challenge were urine samples collected at baseline and at 2, 4, and 6 hours after a fall in FEV₁ of $\geq 20\%$ or after the administration of the second capsule of placebo.

TABLE II. Baseline values of eicosanoids and tryptase in the study groups

	AIA	ATA	HC	P value		
				AIA vs ATA	AIA vs HC	ATA vs HC
Plasma 9 α ,11 β -PGF ₂ (pg/mL)	7.39 $\pm$ 4.19	5.33 $\pm$ 2.97	5.11 $\pm$ 1.73	<.01	<.001	>.05
Serum tryptase (μ g/L)	7.39 $\pm$ 5.86	4.21 $\pm$ 1.77	4.25 $\pm$ 1.30	<.05	<.05	>.05
Urinary 9 α ,11 β -PGF ₂ (ng/mg creatinine)	1.01 $\pm$ 0.57	0.91 $\pm$ 0.65	1.06 $\pm$ 0.51	>.05	>.05	>.05
Urinary LTE ₄ (pg/mg creatinine)	1420.9 $\pm$ 1185.9	482.8 $\pm$ 337.5	336.8 $\pm$ 191.1	<.001	<.001	>.05

Values are expressed as means $\pm$ SDs.

ATA, Aspirin-tolerant asthma; AIA, aspirin-induced asthma; HC, healthy control subjects.

In 10 healthy control-group subjects, the urine samples were collected in the same manner as for the ASA provocation challenge. The samples were taken before and at 2, 4, and 6 hours after a single dose of ASA or placebo. When 3 doses of ASA or placebo were administered, the urine samples were collected only before the first morning dose and then 24 hours later.

Estimations of 9 α ,11 β -PGF₂, tryptase, and leukotriene E₄

Plasma baseline levels of 9 α ,11 β -PGF₂ were analyzed in all 65 ASA-sensitive asthmatics, in all 50 healthy control subjects, and in 47 of 66 patients with ATA. Serum baseline tryptase levels were measured in 29 of 66 patients with ATA, 29 of 65 patients with AIA, and 24 of 50 healthy control subjects. Postchallenge blood samples for 9 α ,11 β -PGF₂ measurements were obtained from 26 patients with AIA and 24 control subjects, whereas for tryptase measurements, samples were taken from 10 patients with AIA and 24 control subjects. Urinary baseline 9 α ,11 β -PGF₂ and leukotriene E₄ (LTE₄) excretions were estimated in all subjects. Postchallenge samples were collected from 26 patients with AIA and 24 control subjects.

9 α ,11 β -PGF₂ was measured in plasma and urine by gas chromatography–negative-ion chemical ionization–mass spectrometry (GC-NICI-MS) after the extraction stage, through use of a C18 Sep-Pak cartridge, derivatization to pentafluorobenzyl ester, thin-layer chromatography purification, and derivatization to trimethylsilyl ether (Hewlett Packard, Palo Alto, Calif). [²H₄]PGF_{2 α} was used as an internal standard in a manner identical to gas chromatography–electron impact mass spectrometry, as reported by Obata et al.¹⁷ Tryptase was measured in serum by a fluoroenzyme-immunoassay method on a UniCAP100 tryptase system (Pharmacia Upjohn Diagnostics, Uppsala, Sweden). LTE₄ excretion was measured in unpurified samples¹¹ by ELISA (Cayman Chemicals, Ann Arbor, Mich) and expressed in picograms per milligram of creatinine.

Skin tests

Skin prick tests with 14 common aeroallergens (Soluprick, ALK, Hørsholm, Denmark) were performed. The positive control was histamine hydrochloride (1 mg/mL). The diluent for the allergens tested was used as a negative control. A positive skin prick test was defined as a wheal with a mean diameter 3 mm larger than that of the negative control.

Qualitative measurement of specific IgE

A qualitative in vitro assay for the differential determination of specific IgE to allergens was pursued in serum by a fluoroenzyme-immunoassay method through use of the PharmaciaCAP System Phadiatop (Pharmacia Upjohn Diagnostics). The cutoff point for positive and negative results was 0.35 kU/L.

Statistical methods

Significance between 3 groups of subjects under baseline conditions was calculated by 1-way ANOVA for independent variables, followed by the least significant difference test for the paired comparison. The relations between baseline and postchallenge levels were assessed by a repeated-measures ANOVA for dependent variables. Correlation between variables was estimated with the Pearson correlation coefficient. Statistical significance was defined at *P* < .05. Results were expressed as means $\pm$ SDs. Statistical evaluation was facilitated by a validated statistical software package, Statistica for Windows (version 5.5; StatSoft, Tulsa, Okla).

The protocol was approved by the local Ethics Committee, and written, informed consent was obtained from each subject.

RESULTS

Clinical observations

In all ASA-sensitive asthmatic individuals undergoing oral ASA challenge, the provocation caused dyspnea and a decrease of FEV₁ of $\geq 20\%$. Nasal symptoms in the form of nasal discharge developed in 14 subjects, whereas nasal blockage occurred in 10 of them. Eleven patients experienced itching of the eyes. Facial flush was recorded in 3 patients, headache in 4 patients, and gastrointestinal discomfort in 4 subjects. The symptoms were relieved by short-acting β_2 -agonists. Systemic corticosteroids were required in 3 cases only. No severe, life-threatening reactions were observed. Placebo challenge was negative in all patients. In all 35 patients with ATA and in 24 control subjects, the ASA challenge was reported as negative.

Eicosanoids and tryptase baseline values

When mean baseline plasma levels of PGD₂ metabolite were compared, the highest values were recorded in patients with AIA (Table II). The levels measured in patients with ATA and healthy control subjects were similar and significantly lower than those of the AIA group. The increased mean baseline PGD₂ levels were manifested as a constant feature; in 26 patients with AIA who had undergone ASA challenge and had baseline measurements repeated on 2 consecutive days (placebo and ASA days), no significant differences were encountered (*P* > .05). There were no correlations between the dose of systemic corticosteroids and baseline levels of 9 α ,11 β -PGF₂ in patients with either AIA or ATA who were receiving such therapy.

TABLE III. Plasma $9\alpha,11\beta$ -PGF₂ and serum tryptase levels at baseline and after ASA challenge

	n	Baseline*	5 min	30 min	60 min	120 min
$9\alpha,11\beta$ -PGF ₂ (pg/mL)						
Placebo	26	6.68 ± 1.97	6.06 ± 2.03	6.19 ± 2.21	6.2 ± 2.09	6.13 ± 1.98
Aspirin	26	6.97 ± 3.27	9.59 ± 6.19†	8.81 ± 5.85	7.7 ± 4.82	6.87 ± 6.87
Tryptase (μg/L)						
Placebo	10	5.82 ± 2.09	5.08 ± 1.97	5.05 ± 1.82	5.14 ± 1.91	5.15 ± 1.67
Aspirin	10	5.85 ± 2.01	7.32 ± 3.47†	8.22 ± 4.81†	8.74 ± 5.31†	10.75 ± 6.61†

Values are expressed as means ± SDs.

*Baseline values calculated for patients in whom postchallenge samples were taken.

†Levels significantly different from baseline ($P < .05$).

TABLE IV. Urinary $9\alpha,11\beta$ -PGF₂ and LTE₄ levels at baseline and after ASA challenge

	n	Baseline*	0-2 h	2-4 h	4-6 h
$9\alpha,11\beta$ -PGF ₂ (ng/mg creatinine)					
Placebo	26	1.15 ± 0.37	1.06 ± 0.03	0.99 ± 0.34	0.99 ± 0.38
Aspirin	26	1.10 ± 0.32	1.20 ± 0.65	1.02 ± 0.37	1.15 ± 0.36
LTE ₄ (pg/mg creatinine)					
Placebo	26	1416.0 ± 1221.4	1409.1 ± 1060.6	1388.7 ± 1040.1	1332.2 ± 1041.1
Aspirin	26	1495.8 ± 1181.6	2447.6 ± 2597.4†	5473.3 ± 6035.7†	7743.3 ± 9922.7†

Values are expressed as means ± SDs.

*Baseline values calculated for patients from whom postchallenge samples were taken.

†Levels significantly different from baseline ($P < .05$).

Patients with AIA showed the highest baseline tryptase values in comparison with the other 2 groups (Table II). There were no significant differences between the levels measured in the ATA group and the levels measured in the control subjects with respect to this metabolite.

There were no differences in baseline urinary excretion of $9\alpha,11\beta$ -PGF₂ in any of the 3 groups (Table II). In patients with ATA the mean baseline level of urinary LTE₄ excretion was not significantly different from that in healthy control subjects (Table II). Patients with AIA had the highest levels of urinary LTE₄, significantly different from the values recorded in both the ATA group and the healthy control group (Table II).

Plasma $9\alpha,11\beta$ -PGF₂ after ASA challenge

In ASA-sensitive asthmatic patients, ASA caused a significant, early mean 1.4-fold rise in $9\alpha,11\beta$ -PGF₂ level in blood in comparison with the prechallenge value ($P < .05$; Table III). At the later time points (30 and 60 minutes) the levels showed a tendency to higher readings in comparison with baseline values, though the differences failed to reach statistical significance ($P > .05$). In individual patients the response was not homogeneous. The rise (1.4- to 7-fold) was observed in 15 patients, there was no change in 7, and a decrease (by 1.4- to 2.5-fold) was seen in 4 subjects. After placebo administration, no significant differences were found between the mean baseline value and the values measured at all sampling time points (Table III). ASA administered in different doses to healthy volunteers did not affect the post-ASA blood levels of $9\alpha,11\beta$ -PGF₂.

Serum tryptase after ASA challenge

ASA provocation was followed by a gradual significant rise in serum tryptase levels, which began 5 minutes after the challenge ($P < .05$) and reached the peak 120 minutes after the provocation ($P < .01$; Table III). Such positive response occurred in 8 of 10 patients from whom postchallenge samples for tryptase measurements were collected. Placebo had no effect (Table III).

Urinary $9\alpha,11\beta$ -PGF₂ after ASA challenge

After the ASA challenge, at no time did the mean values show statistically significant differences compared with baseline (Table IV). Measurements in individual patients revealed a moderate rise (1.3- to 2.6-fold) in 11, no change in 7, and a fall (by 1.3 to 1.7) in 8. Likewise, placebo administration did not cause any significant differences in urinary levels of this metabolite (Table IV). Ingestion of different doses of ASA did not affect the urinary $9\alpha,11\beta$ -PGF₂ excretion in healthy control subjects.

Urinary LTE₄ after ASA challenge

All patients with AIA who were subjected to the ASA provocation test responded to the challenge with a rise in urinary LTE₄ excretion. The peak values increased by 1.4 to 23 times over the baseline values. The mean LTE₄ value was found to have risen by 1.7-fold over baseline in the samples collected between 0 and 2 hours ($P < .05$; Table IV). It continued to rise and reached its peak in the last sample collected (ie, 4 to 6 hours after the ASA challenge); it was 5-fold higher in comparison with baseline

($P < .01$; Table IV). The levels measured before and after placebo administration were relatively stable and did not differ statistically (Table IV).

In the group of healthy control subjects, LTE_4 urinary excretions showed no statistical differences at any of the sampling times compared with baseline values, irrespective of the ASA dose actually administered.

Analysis of correlation between the variables studied

No correlation was found between the following variables: (1) plasma and urinary levels of $9\alpha,11\beta\text{-PGF}_2$; (2) plasma $9\alpha,11\beta\text{-PGF}_2$ and serum tryptase levels; and (3) urinary LTE_4 and urinary $9\alpha,11\beta\text{-PGF}_2$ levels, before and after ASA challenge.

DISCUSSION

Because of rapid metabolism and artifactual generation of prostaglandins during sampling and isolation of plasma, it is widely recognized that measuring metabolites rather than the parent compound is by far the most efficacious method of assessing the endogenous production of prostaglandins.^{18,19} The predominant pathway of PGD_2 metabolism has been shown to involve transformation of PGD_2 by the 11-keto-reductase enzyme to $9\alpha,11\beta\text{-PGF}_2$. This metabolite does in fact boast biologic activity. It is equipotent with PGD_2 in causing constriction of human airways in vitro and in vivo,²⁰ it contracts isolated human coronary arteries,²¹ and it inhibits platelet aggregation.²² The mass spectrometry measurement of PGD_2 metabolites in blood is highly accurate and sensitive, though not very efficient, and therefore requires expensive instrumentation. Very limited data are available on $9\alpha,11\beta\text{-PGF}_2$ levels in human blood. In 3 asthmatic children,¹⁷ plasma levels of $9\alpha,11\beta\text{-PGF}_2$ were lower at the time of discharge from hospital in comparison with those on admission, though they all remained within the range for healthy subjects. In the case of acute urticaria and bronchospasm of unknown origin,¹⁹ the level of $9\alpha,11\beta\text{-PGF}_2$ was 5 pg/mL—ie, in the upper range for normal individuals studied by the authors (average, 3 pg/mL). A very high level (143 pg/mL) was recorded in single cases of mastocytosis.^{19,23}

In a group of patients with AIA assessed in the present study, the mean baseline $9\alpha,11\beta\text{-PGF}_2$ plasma levels were significantly higher than in both the patients with ATA and the healthy control subjects. The elevation of this biomarker appeared to be a constant feature, because it was recorded in the blood sampled on 2 consecutive days in the same group of subjects with AIA. The most likely cellular sources of PGD_2 were mast cells, which infiltrate airway smooth muscle in asthma.²⁴ It was then interesting to note that the mean baseline levels of serum tryptase, another marker of mast cell activation, also showed the highest values in the AIA group in comparison with the other 2 groups. A rise in PGD_2 and tryptase levels at baseline suggests an ongoing process of mast cell and/or macrophage activation in stable AIA. It also

indicates that in AIA, a second arachidonate metabolite, apart from cysteinyl leukotrienes, is overproduced. Exacerbation of asthma can lead to a rise in plasma PGD_2 . Hence, in a group of asthmatic patients, including those with AIA, $9\alpha,11\beta\text{-PGF}_2$ plasma levels were significantly higher at exacerbation than at recovery.²⁵ A striking increase of eosinophils in AIA airways²⁶ might therefore account for the ongoing mast cell activation. Eosinophils have the capability to generate and excrete stem cell factor. This is the only factor essential for human mast cell development and is a powerful direct activator of the mediator release by mature mast cells.²⁷

ASA challenge performed in patients with AIA caused an early 1.4-fold increase in plasma $9\alpha,11\beta\text{-PGF}_2$, which was short-lasting, albeit statistically significant. The response was not homogeneous. Only approximately 65% of the subjects responded with an evident increase in PGD_2 metabolite. Such a nonhomogeneous response was observed previously after an ASA challenge, when PGD_2 was measured in bronchoalveolar lavage fluid²⁸ or in urine.²⁹ Two isoforms of cyclooxygenase (COX) coexpress in the same cell types, but their proportions can vary.³⁰ This different proportion might affect the extent of COX inhibition by ASA, a nonselective inhibitor. Specific COX2 inhibitors do not trigger cysteinyl leukotrienes and PGD_2 release in the patients with AIA.³¹ The concomitant increase in serum tryptase levels after ASA challenge, as observed in patients with AIA assessed in the present study, provides additional support for the assumption that in this type of asthma, mast cells are activated by ASA, as already suggested by other authors.³² This is also consistent with the results of our previous study³³ of a group of 10 patients with AIA, in whom the mean serum tryptase level was found to increase significantly within 4 hours of ASA ingestion. Results obtained by others³⁴ were far from equivocal; marked elevations of tryptase levels in post-ASA serum samples were observed in only 3 of 17 subjects studied.

In urine, as opposed to plasma, baseline $9\alpha,11\beta\text{-PGF}_2$ levels were similar in the 3 groups studied, as earlier reported.¹² In the AIA group investigated in the present study, ASA provocation did not cause evident changes in postchallenge values of this metabolite. This result is in opposition to the observations of O'Sullivan et al¹² and Mita et al,¹³ who reported an increase in urinary $9\alpha,11\beta\text{-PGF}_2$ after ASA challenges in patients with AIA. Different routes of administration (inhaled¹² or intravenous¹³) and different assay methods might well account for these discrepancies. The authors of both of the aforementioned studies used the same enzyme-immunoassay method, whereas the GC-NICI-MS method was applied in the present study. The former measures the sum of $9\alpha,11\beta\text{-PGF}_2$ and 2 isomers of its dinor metabolite, whereas the latter is restricted to the detection of $9\alpha,11\beta\text{-PGF}_2$.³⁵ Hence, when a major PGD_2 urinary metabolite,³⁶ PGD-M ($9\alpha,11\beta$ dihydroxy-15-oxo-2,3,18,19-tetranorprost-5-ene-1,20 dioic acid), was determined by GC-NICI-MS in patients with AIA after the ASA challenge, the mean levels of this metabolite remained unaltered, although in 6

of 9 patients studied, a mild rise occurred.²⁹ Apart from $9\alpha,11\beta$ -PGF₂ and PGD₂-M, other PGD₂ metabolites are excreted in urine.³⁷ Various activities of the enzymes that metabolize PGD₂ in blood and tissues might therefore account for the lack of correlation between plasma and urinary levels of the PGD₂ metabolite investigated in the present study.

PGD₂ released in patients with asthma might affect the clinical presentation of asthma through its bronchoconstrictive action and potent chemoattractive properties for T_H2 lymphocytes, basophils, and eosinophils.³⁸ The role of PGD₂ degradation products via nonenzymatic chemical modification (eg, 15-deoxy PGJ₂) and their interaction with proliferator-activated receptors remains a matter of controversy.³⁹ Half of patients with AIA require long-term oral corticotherapy to control their asthma.⁴⁰ A steady mast cell activation with PGD₂ release might be one of the key reasons for the severe course of this particular type of asthma.

Different mechanisms might operate in other phenotypes of asthma. Pretreatment with indomethacin prevented an increase in a stable PGD₂ urinary metabolite but did not affect the airway response to the inhaled allergen in atopic asthmatic patients.⁴¹ COX inhibition by indomethacin, however, might also prevent synthesis of "beneficial" prostaglandins—ie, PGE₂⁴²—or cause an increase in the amount of constrictor 5-lipoxygenase products formed by activated cells.⁴³

No correlation was found in the present study between urinary LTE₄ and plasma or urinary PGD₂ metabolite at baseline or after the ASA challenge. These complex issues await further studies.

It was surprising to find that in healthy subjects, even the high doses of ASA failed to diminish blood and urinary levels of the stable PGD₂ metabolite. This is in contrast with the inhibitory effects of ASA on *in vivo* biosynthesis of other prostanoids, such as prostacyclin and thromboxane A₂,⁴⁴ and might point to an unknown regulatory mechanism in COX-mediated production of PGD₂.

As evidenced by the present study, in stable AIA as opposed to stable ATA, there is a steady release of PGD₂ into blood. This implicates a continuous activation of mast cells and/or macrophages, which is further corroborated by the concomitant elevation in baseline levels of tryptase. A specific trigger, such as ASA, enhances the ongoing release of both of these substances in the majority of, though not in all, patients with AIA. Enhanced PGD₂ release might be related to a severe clinical course of AIA. The clinical value of plasma $9\alpha,11\beta$ -PGF₂ measurements warrants further studies.

REFERENCES

- Murray JJ, Tonnel AB, Brash AR, Roberts LJ, Gosset P, Workman R, et al. Release of prostaglandin D₂ into human airways during acute antigen challenge. *N Engl J Med* 1986;315:800-4.
- Narumiya S. Structures, properties and distributions of prostanoid receptors. *Adv Prostagl Thrombox Leukot Res* 1995;23:17-22.
- Matsouka T, Horata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, et al. Prostaglandin D₂ as a mediator of allergic asthma. *Science* 2000;287:2013-7.
- Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF Jr, Meyers DA, Norman PS, et al. Mediator release after nasal airway challenge with allergen. *Am Rev Respir Dis* 1983;128:597-602.
- Pienkowski MM, Adkinson NF Jr, Plaut M, Norman PS, Lichtenstein LM. Prostaglandin D₂ and histamine during the immediate and the late-phase components of allergic cutaneous responses. *J Allergy Clin Immunol* 1988;82:95-100.
- Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J₂ inhibits multiple steps in the NF- κ B signaling pathway. *Proc Natl Acad Sci U S A* 2000;97:4844-9.
- Laine P, Naukkarinen A, Heikkilä L, Penttillä A, Kovanen PT. Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. *Circulation* 2000;101:1665-9.
- Laine P, Kaartinen M, Penttillä A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. *Circulation* 1999;99:361-9.
- Wood-Barker R, Finnerty JP, Holgate ST. Plasma and urinary histamine in allergen-induced early and late asthmatic responses. *Eur Respir J* 1993;6:1138-44.
- Schwartz LB, Atkins PC, Bradford TR, Fleekop P, Shalit M, Zweiman B. Release of tryptase together with histamine during the immediate cutaneous response to allergen. *J Allergy Clin Immunol* 1987;80:850-5.
- O'Sullivan S, Roquet A, Dahlén B, Dahlén SE, Kumlin M. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. *Clin Exp Allergy* 1998;28:1332-9.
- O'Sullivan S, Dahlén B, Dahlén SE, Kumlin M. Increased urinary excretion of the prostaglandin D₂ metabolite $9\alpha,11\beta$ -prostaglandin F₂ after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. *J Allergy Clin Immunol* 1996;98:421-32.
- Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M, et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. *Allergy* 2001;56:1061-7.
- Nagakura T, Obata T, Shichijo K, Matsouda S, Sigimoto H, Yamashita K, et al. GC/MS analysis of urinary excretion of $9\alpha,11\beta$ -PGF₂ in acute and exercise-induced asthma in children. *Clin Exp Allergy* 1998;28:181-6.
- Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. *J Allergy Clin Immunol* 1999;104:5-13.
- Nizankowska E, Bestyńska-Krypel A, Ćmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. *Eur Respir J* 2000;15:863-9.
- Obata T, Nagakura T, Kammuri M, Masaki T, Maekawa K, Yamashita K. Determination of $9\alpha,11\beta$ -prostaglandin F₂ in human urine and plasma by gas chromatography-mass spectrometry. *J Chromatogr B* 1994;655:173-8.
- Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. *Annu Rev Biochem* 1975;44:669-95.
- Awad JA, Morrow JD, Roberts LJ. Detection of the major urinary metabolite of prostaglandin D₂ in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. *J Allergy Clin Immunol* 1994;93:817-24.
- Beasley CRW, Robinson C, Featherstone RL, Varley JG, Hardy CC, Church MK, et al. $9\alpha,11\beta$ -prostaglandin F₂, a novel metabolite of prostaglandin D₂ is a potent contractile agonist of human and guinea pig airways. *J Clin Invest* 1987;79:978-82.
- Robertson RM, Liston T, Tantengco MV, Roberts LJ. Human coronary arteries are contracted by a novel prostaglandin [abstract]. *Clin Res* 1985;33:A221.
- Roberts LJ, Liston TE. $9\alpha,11\beta$ -prostaglandin F₂: a new biologically active prostaglandin formed *in vivo* in humans [abstract]. *Clin Res* 1985;33:A162.
- Bazan-Socha S, Rudzki Z, Maciejewicz J, Witkoś T, Szczeklik A. Clinical variability in two cases of systemic mastocytosis [in Polish]. *Pol Arch Med Wewn* 2001;55:311-5.
- Brigtling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. *N Engl J Med* 2002;346:1699-705.
- Bochenek G, Nagraba K, Gielicz A, Nizankowska E, Szczeklik A. Prostaglandin D₂ metabolite as a marker of asthma exacerbations. *Eur Respir J* 2002;20(suppl 38):424s.
- Sampson AP, Cowburn AS, Stadek K, Adamek Ł, Nizankowska E, Szczeklik A, et al. Profound overexpression of leukotriene C₄ synthase in aspirin-intolerant asthmatic bronchial biopsies. *Int Arch Allergy Immunol* 1977;113:355-7.

27. Smith SJ, Piliponsky AM, Hartman ML, Levi-Schaffer F. Stem cell factor: a possible paradigm between mast cells, eosinophils, and fibroblasts. *ACI Int* 2002;14:52-9.
28. Szczeklik A, Sładek K, Dworski R, Niżankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. *Am J Respir Crit Care Med* 1996;154:1608-14.
29. Szczeklik A, Dworski R, Mastalerz L, Prokop A, Sheller J, Niżankowska E, et al. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. *Am J Respir Crit Care Med* 1998;158:1168-72.
30. Taha R, Olivenstein R, Utsumi T, Ernst P, Barnes PJ, Rodger IW, et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;161:636-40.
31. Szczeklik A, Niżankowska E, Bochenek G, Nagraha K, Mejza F, Świerczyńska M. Safety of specific COX2 inhibitor in aspirin-induced asthma. *Clin Exp Allergy* 2001;31:219-25.
32. Fisher AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. *J Allergy Clin Immunol* 1994;94:1046-56.
33. Sładek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. *Eur Respir J* 1993;6:391-9.
34. Bosso JV, Schwartz LB, Stevenson DD. Tryptase and histamine release during aspirin-induced respiratory reactions. *J Allergy Clin Immunol* 1991;88:830-7.
35. O'Sullivan S, Mueller MJ, Dahlén SE, Kumlin M. Analyses of prostaglandin D₂ metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionization gas chromatography-mass spectrometry. *Prostaglandins Other Lipid Mediat* 1999;57:149-65.
36. Liston TE, Roberts LJ II. Metabolite fate of radiolabelled prostaglandin D₂ in a normal human male volunteer. *J Biol Chem* 1985;260:13172-80.
37. Giles H, Leff P. The biology and pharmacology of PGD₂. *Prostaglandins* 1988;35:277-300.
38. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D₂ selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. *J Exp Med* 2001;193:255-61.
39. Serhan CN, Devhand PR. Novel anti-inflammatory targets for asthma: a role for PPARγ? *Am J Respir Cell Mol Biol* 2001;2:658-61.
40. Szczeklik A, Niżankowska E, Duplaga M, on behalf of the AIANE Investigators. Natural history of aspirin-induced asthma. *Eur Respir J* 2000;16:432-6.
41. Sładek K, Sheller JR, Fitzgerald GA, Morrow JD, Roberts LJ. Formation of PGD₂ after allergen inhalation in atopic asthmatics. In: Samuelsson B, et al, editors. *Advances in prostaglandin, thromboxane and leukotriene research*. New York: Raven Press; 1990. p. 433-6.
42. Hartet TV, Dworski RT, Mellen BG, Oates JA, Murray JJ, Sheller JR. Prostaglandin E₂ decreases allergen-stimulated release of prostaglandin D₂ in airways of subjects with asthma. *Am J Respir Crit Care Med* 2000;162:637-40.
43. Kuehl FA, Dougherty WH, Ham EA. Interactions between prostaglandin and leukotrienes. *Biochem Pharmacol* 1984;33:1-5.
44. Vane JR, Botting RM. The mechanism of action of aspirin. In: Vane JR, Botting RM, editors. *Aspirin and other salicylates*. London: Chapman and Hall; 1991. p. 35-62.